Filtered By:
Condition: Heart Failure
Drug: Coumadin

This page shows you your search results in order of date. This is page number 8.

Order by Relevance | Date

Total 289 results found since Jan 2013.

Left atrial appendage exclusion: An alternative to anticoagulation in nonvalvular atrial fibrillation
Patients with atrial fibrillation (AF) are 5 times more likely to have a stroke than individuals in sinus rhythm, and 1 in every 5 strokes is secondary to AF.1-3 Unfortunately, AF-related thrombo-emboli are larger and result in ischemic strokes that are more devastating than those secondary to carotid artery disease or other etiologies.4,5 Lifelong oral anticoagulation with warfarin has been the guideline-based therapy to reduce the risk of AF-related ischemic strokes in patients with a CHA2DS2-VASc (congestive heart failure, hypertension, age>75 and diabetes mellitus, previous history of stroke or transient ischemic attac...
Source: The Journal of Thoracic and Cardiovascular Surgery - February 2, 2017 Category: Cardiovascular & Thoracic Surgery Authors: Kareem Bedeir, David R. Holmes, James L. Cox, Basel Ramlawi Tags: Expert review Source Type: research

Choosing Non-Vitamin K Antagonist Oral Anticoagulants: Practical Considerations We Need to Know.
CONCLUSION: NOACs provide a convenient and safe alternative to warfarin and may result in improved therapeutic outcomes for patients with NVAF or VTE. The use of NOACs in other indications and patient populations is under investigation, and clinical trials investigating their use in acute coronary syndrome, medically ill patients, percutaneous coronary intervention, cardioversion, catheter ablation, coronary arterial disease, and heart failure have been announced. PMID: 27999513 [PubMed]
Source: Ochsner Journal - December 23, 2016 Category: Journals (General) Tags: Ochsner J Source Type: research

How I use anticoagulation in atrial fibrillation
Atrial fibrillation is the most common cardiac arrhythmia and conveys a significant risk of morbidity and mortality due to related stroke and systemic embolism. Oral anticoagulation (OAC) is the mainstay of thromboembolism prevention, and management of anticoagulation can be challenging. For patients without significant valvular disease, decisions around anticoagulation therapy are first based on the presence of additional stroke risk factors, as measured by the CHA2DS2-VASc (congestive heart failure, hypertension, age ≥75, diabetes, prior stroke or transient ischemic attack, vascular disease, age 65–74, and sex c...
Source: Blood - December 21, 2016 Category: Hematology Authors: Steinberg, B. A. Tags: How I Treat, Free Research Articles, Thrombosis and Hemostasis Source Type: research

How safe are non-vitamin K antagonist oral anticoagulants in atrial fibrillation?
This article expands on the concept of the ‘net clinical benefit’ and on how this may inform clinical decisions, reinforcing the perception of NOACs as better drugs than VKAs in preventing stroke in AF.
Source: European Journal of Heart Failure Supplements - December 21, 2016 Category: Cardiology Authors: De Caterina, R. Tags: Articles Source Type: research

What do the guidelines suggest for non-vitamin K antagonist oral anticoagulant use for stroke prevention in atrial fibrillation?
This article provides an overview of the current international guidelines with regard to NOAC use and highlights key areas by which emerging evidence may change the management of stroke prevention in patients with non-valvular AF.
Source: European Journal of Heart Failure Supplements - December 21, 2016 Category: Cardiology Authors: Shahid, F., Shantsila, E., Lip, G. Y. H. Tags: Articles Source Type: research

Causes of Death in Anticoagulated Patients With Atrial Fibrillation
ConclusionsIn contemporary AF trials, most deaths were cardiac-related, whereas stroke and bleeding represented  only a small subset of deaths. Interventions beyond anticoagulation are needed to further reduce mortality in AF.
Source: Journal of the American College of Cardiology - December 5, 2016 Category: Cardiology Source Type: research

Letter by Chen et al Regarding Article, “Left Ventricular Eȷection Fraction and Risk of Stroke and Cardiac Events in Heart Failure: Data From the Warfarin Versus Aspirin in Reduced Eȷection Fraction Trial” Letter to the Editor
Source: Stroke - November 27, 2016 Category: Neurology Authors: Chen Chen, Dongze Li, Lixia Deng Tags: Arrhythmias, Heart Failure, Complications, Cerebrovascular Disease/Stroke Letters to the Editor Source Type: research

Response by Di Tullio et al to Letter Regarding Article, “Left Ventricular Eȷection Fraction and Risk of Stroke and Cardiac Events in Heart Failure: Data From the Warfarin Versus Aspirin in Reduced Eȷection Fraction Trial” Letter to the Editor
Source: Stroke - November 27, 2016 Category: Neurology Authors: Marco R. Di Tullio, John L.P. Thompson, Shunichi Homma, for the WARCEF Investigators Tags: Heart Failure, Cerebrovascular Disease/Stroke Letters to the Editor Source Type: research

Pre-treatment clinical assessment in head and neck cancer: United Kingdom National Multidisciplinary Guidelines.
Authors: Robson A, Sturman J, Williamson P, Conboy P, Penney S, Wood H Abstract This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer patients in the UK. This paper provides recommendations on the pre-treatment clinical assessment of patients presenting with head and neck cancer. Recommendations • Comorbidity data should be collected as it is important in the analysis of survival, quality of life and functional outcomes after treatment as well as for comparing results of different treatment regimens and different centres. (R) • Patients with hypertens...
Source: Journal of Laryngology and Otology - November 15, 2016 Category: ENT & OMF Tags: J Laryngol Otol Source Type: research

Is an Oral Anticoagulant Necessary for Young Atrial Fibrillation Patients With a CHA2DS2-VASc Score of 1 (Men) or 2 (Women)? Arrhythmia and Electrophysiology
ConclusionsFor atrial fibrillation patients aged 20 to 49 years with 1 risk factor in addition to sex, non–vitamin K antagonist OACs should be considered for stroke prevention to minimize the risk of a potentially fatal or disabling event.
Source: JAHA:Journal of the American Heart Association - October 3, 2016 Category: Cardiology Authors: Hung, Y., Chao, T.-F., Liu, C.-J., Tuan, T.-C., Lin, Y.-J., Chang, S.-L., Lo, L.-W., Hu, Y.-F., Liao, J.-N., Chung, F.-P., Lin, W.-Y., Lin, W.-S., Cheng, S.-M., Chen, T.-J., Lip, G. Y. H., Chen, S.-A. Tags: Atrial Fibrillation Original Research Source Type: research

Validation of a Modified CHA2DS2-VASc Score for Stroke Risk Stratification in Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study Clinical Sciences
Conclusions— In this Asian atrial fibrillation cohort, the mCHA2DS2-VASc score performed better than the CHA2DS2-VASc and would further identify atrial fibrillation patients who may derive a positive net clinical benefit from oral anticoagulation.
Source: Stroke - September 25, 2016 Category: Neurology Authors: Chao, T.-F., Lip, G. Y. H., Liu, C.-J., Tuan, T.-C., Chen, S.-J., Wang, K.-L., Lin, Y.-J., Chang, S.-L., Lo, L.-W., Hu, Y.-F., Chen, T.-J., Chiang, C.-E., Chen, S.-A. Tags: Atrial Fibrillation Clinical Sciences Source Type: research

Factors associated with abrupt discontinuation of dabigatran therapy in patients with atrial fibrillation in Malaysia
Conclusion Abrupt dabigatran discontinuation without an alternative oral anticoagulant increases the risk of thromboembolic events. As adverse drug events and renal impairment contribute substantially to the premature discontinuation of dabigatran, it is important to identify and monitor patients at risk to reduce dabigatran discontinuation rate especially during the first six months of dabigatran therapy.
Source: International Journal of Clinical Pharmacy - September 21, 2016 Category: Drugs & Pharmacology Source Type: research

Right Ventricular Dysfunction Complicates Time in Therapeutic Range in Heart Failure Patients Receiving Warfarin
Conclusions: The present study demonstrated that presence of RVD in HF increases the risk for poor anticoagulation.Pharmacology 2017;99:19-26
Source: Pharmacology - September 21, 2016 Category: Drugs & Pharmacology Source Type: research

The C of CHADS: Historical Perspective and Clinical Applications for Anticoagulation in patients with Non Valvular Atrial Fibrillation and Congestive Heart Failure
The risk stratification of patients with coexisting non valvular atrial fibrillation and congestive heart failure, is often a clinical challenge, as the definitions of congestive heart failure in the popular CHADS2 and CHA2DS2VASc scoring systems, and amongst major clinical trials on Warfarin and Novel Oral Anticoagulants (NOAC) have heterogeneity. Available evidence reveals that any heart failure and/or left ventricular systolic dysfunction is associated with higher rates of stroke/systemic embolism and bleeding in patients with non valvular atrial fibrillation compared to patients without heart failure and normal left ventricular function.
Source: International Journal of Cardiology - September 16, 2016 Category: Cardiology Authors: Y Chugh, RT Faillace Tags: Editorial Source Type: research

Antiplatelet versus anticoagulation treatment for patients with heart failure in sinus rhythm.
CONCLUSIONS: There is evidence from RCTs to suggest that neither oral anticoagulation with warfarin or platelet inhibition with aspirin is better for mortality in systolic heart failure with sinus rhythm (high quality of the evidence for all-cause mortality and moderate quality of the evidence for non-fatal cardiovascular events and major bleeding events). Treatment with warfarin was associated with a 20% reduction in non-fatal cardiovascular events but a twofold higher risk of major bleeding complications (high quality of the evidence). We saw a similar pattern of results for the warfarin versus clopidogrel comparison (lo...
Source: Cochrane Database of Systematic Reviews - September 14, 2016 Category: Journals (General) Authors: Shantsila E, Lip GY Tags: Cochrane Database Syst Rev Source Type: research